Targeted Oncology4 小时
Iomab-B Leads to More Durable Responses vs alloHCT in AML Treatment
Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...
Targeted Oncology1 天
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...
Cancer Therapy Advisor1 天
CAR T-Cell Therapy Shows Activity in Metastatic CRC
A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.
Nature5 天
Haematological diseases articles from across Nature Portfolio
Haematological diseases are pathological conditions primarily affecting the blood or blood-producing organs. This group of disorders includes, but is not limited to, various types of anaemia ...
Medscape1 天
The Concurrent Chemoradiation Paradigm-General Principles
Summary and Introduction Clinical Application—Disease Entities Theoretical Framework for Therapy−The 'Steel Paradigm' Conclusion References Theoretical Framework for Therapy−The 'Steel ...
pharmaphorum1 天
Immunocore and GSK pick third cancer immunotherapy target
The company has since decided to add fludarabine as a conditioning agent to boost responses, even though this practice came under suspicion when deaths occurred in Juno’s CAR-T trials.
Medscape4 天
Drug Incompatibility Chemistry
Most organic drugs contain one acid group, usually a carboxylic acid, -COOH, or one basic primary, secondary, or tertiary amino group, NC 1-3, [3,22,27,28,29] that determines the acid-base ...